neuroplasticity

This Year in Psychedelics - 2021

Before we get into this recap of the biggest psychedelic news stories from 2021, I’d like to address the fact that this blog post is coming out a month late. Normally I strive to publish my yearly recaps on New Year’s Eve, but things have been really hectic on my end lately and I’ve been barely keeping up with putting out the weekly link roundups, much less creating monthly and yearly recaps or other types of content.

So I apologize for not getting this out into the world sooner. I’ve started to realize that I bit off way more than I can chew over the last year and fell behind on things here at Think Wilder. Here’s hoping 2022 will be a little more focused so I can meet my deadlines and get my work out in a timely manner for y’all to enjoy!

Just like last month’s recap, there is no video recap of this year’s psychedelic news recap up on YouTube. I’ll have another update about some changes coming to my YouTube channel that should hopefully be out later this week on my channel, so make sure you subscribe there if you’d like to be informed about things on that front.

Moving on to the main show, there was a ton of huge news in 2021. Without further ado, let’s jump into the news.

Policy

Wins

Nine U.S. cities decriminalized psychedelics:

When it comes to cannabis policies there were several successes at the state level, even though attempts to change things at the federal level were unsuccessful. Four states legalized weed:

In addition, Alabama legalized medical marijuana and New Jersey and Louisiana decriminalized cannabis.

Taking things a bit further, Baltimore, MD and Scotland decriminalized the use of all drugs.

The governors of Connecticut and Texas signed legislation that will enable the states to study the therapeutic potential of psychedelics. And New Zealand legalized drug checking, becoming the world’s first country to do so.

Industry

One of the biggest stories in the psychedelic industry involved the fight over patenting various aspects involving psychedelics. The one that probably stirred up the most discontent was when COMPASS Pathways submitted a patent application that attempted to claim the right to common, preexisting psychedelic therapy techniques. This prompted a discussion about patents in psychedelia, with many people wondering if companies should own the future of the field. COMPASS Pathways has five U.S. patents and a total of ten worldwide, so they are quickly claiming rights to a lot of intellectual property in the space. But not without a fight—last month a non-profit known as Freedom to Operate submitted a new legal filing that argues against COMPASS Pathways’ patent on its form of synthetic psilocybin based on the idea that it is not a novel invention. The results from this case will set a precedent for not just COMPASS Pathways but for other psychedelic companies as well.

Psychedelic companies started making waves on the stock markets around the world, with five companies joining the Nasdaq (Mindmed, atai Life Sciences, Field Trip Health, Enveric Biosciences, and Bright Minds Biosciences) and Cybin joining the New York Stock Exchange.

Psychedelic companies secured a historic amount of funding, estimated at a cool $2 billion.

A few other interesting stories in the realm of psychedelic industry from 2021:

Research

Published Studies

Several studies came out:

Future Studies

Looking ahead:

  • A study looking to treat tobacco addiction with psilocybin will receive federal funding

  • The NIH granted Yale nearly $200k to fund the studying of psilocybin for depression and obsessive-compulsive disorder

  • The Australian government earmarked $15 million for psychedelic research

  • The DEA has proposed a dramatic increase in the production of cannabis and psychedelics for research in 2022

Research Centers

A record-breaking number of psychedelic research centers were announced or opened:

In addition to these new psychedelic research centers, Harvard Law School’s Project on Psychedelics Law and Regulation will contribute to the effort to create evidence-based laws and policies involving psychedelics.

Harm Reduction

The FDA and CDC issued warnings to consumers about potential risks involving delta-8 THC, a relatively new psychoactive cannabinoid that has grown in popularity due to its widespread legality but remains essentially unregulated at this time. Apparently there has been a significant increase in reported adverse health effects from people using this drug.

However, before you go ahead and toss any of these products you may already own out of the window, it may be helpful to know that it’s not like people are getting poisoned. In fact, it’s far more likely that they are unintentionally getting high after using delta-8 THC because of misunderstandings, bad labeling, and a lack of experience.

The Fireside Project has been helping people process psychedelic experiences via its free peer support phone line since it launched last April, but the organization took things to the next level by releasing a psychedelic peer support app. Now psychonauts in need of support can find help on either the phone or via chat, which may be helpful for people who prefer one form of communication over another.

Drug checking is an essential practice for any responsible psychonaut, and new technologies are coming out that will ensure more innovative and accurate results than ever before. The popular harm reduction organization known as DanceSafe released a new ketamine test kit (called the Morris reagent) that was engineered to identify the difference between ketamine and common analogues like DCK and 2FDCK. And a startup called Miraculix took things one step further by creating rapid at-home test kits that can assess the potency of various psychoactive drugs, including MDMA, LSD, and psilocybin.

Harm reductionists have yet another tool that can be used to help psychonauts use drugs as safely as possible; a new app called Pill-iD lets users scan pills to see what they contain.

However, it’s not a perfect option because rather than find out what’s actually inside a pill, the app instead uses machine learning to cross-check the user’s image against a large database of scanned pills to provide details about what drug is actually contained within, the risk level from taking it, and any potential side effects.

So while it’s not advisable to rely solely on this new app to find out what’s inside your pill, it could help inform naïve users that there is a possibility they might have bought an adulterated drug. As I’ve tried to hammer home over and over again, it’s always advisable to use a reagent test kit to further rule out the possibility that your pills contain unwanted drugs and to properly weigh your substances before you take them.

Miscellaneous

What a year! Tons of new psychedelic research studies, a streak of drug policy reform wins, the growing psychedelic industry, and several important developments in psychedelic culture… last year was certainly a lot to take in.

Now that you’ve read my recap of the biggest psychedelic news from 2021, I’d like to recommend the following highlights from other publications that you might enjoy:

And lastly, I will leave you with the links to the annual psychedelic news recaps I’ve published over the last six years. I hope you have a wonderful 2022 and make sure you subscribe to my monthly newsletter to keep up-to-date with all the latest psychedelic news.

Previous Years in Psychedelics

That’s all for this year’s update. Remember to always test and weigh your drugs and until next time—keep thinking wilder.

Think Wilder is reader-supported. If you enjoyed this year’s update, please consider helping out by becoming a patron, making a one-time donation, or sharing this post with a friend. Thank you for your support.